Everything below concerns phase 2 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-29. Numbers and descriptions here follow the published literature rather than marketing material.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
== External links == GMP+synthetase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) PDBe-KB provides an overview of all the structure information available in the PDB for Human GMP synthase [glutamine-hydrolyzing]
=== Advocacy and guidelines === Kalra has been the lead or senior author of several national and regional guidelines on obesity and nutrition. He has published several papers highlighting the need for advocacy to address the obesity epidemic in India, including issues of gender disparity. He has also advocated strategies to prevent obesity in the Indian population. Advocacy efforts beyond India include publications highlighting regional challenges and the need for greater collaboration among South Asian countries. He is also a co-author of expert recommendations on the pre-operative and post-operative medical management of patients undergoing bariatric surgery.
By conceptualizing tissue-biofluid as information channels, significant biofluid proxies can be identified and then used for the guided development of clinical diagnostics. Candidate biomarkers are then predicted based on information transfer criteria across the tissue-biofluid channels. Significant biofluid-tissue relationships can be used to prioritize clinical validation of biomarkers.
Such glare can lead to serious accidents and, in the case of pilots and truck drivers, to occupational disability due to eye damage. The first accident prevention regulation was published on April 1, 1988 as BGV B2, followed on January 1, 1997 by DGUV Regulation 11 of the German Social Accident Insurance. Between January and mid-September 2010, the German Federal Aviation Office registered 229 dazzle attacks on helicopters and airplanes of German airlines nationwide. On October 18, 2017, a perpetrator of a dazzle attack on a federal police helicopter was sentenced to one year and six months in prison without parole.
== Honors and awards == 2005 – HUPO Award 2006 – Buchner Medal 2008 – In recognition of his contribution to the field of protein sciences and proteomics the Association of Biomolecular Resource Facilities (ABRF) selected him for the ABRF 2008 Award. 2010 – Herbert A. Sober Lectureship 2010 – Otto Naegeli Prize 2012 – Thomson Medal Award 2014 – he became a member of the German Academy of Sciences Leopoldina. 2015 – ranked #1 on the 2015 list of "most influential people in the analytical sciences" (by the Analytical Scientist) 2018 – Bijvoet Medal of the Bijvoet Center for Biomolecular Research of Utrecht University 2020 – Marcel Benoist Prize 2026 – Canada Gairdner International Award
Sources: en.wikipedia.org
== Chemistry == Levobunolol is the pure L-enantiomer of bunolol and has more than 60 times the pharmacological activity of D-bunolol. It is used as the hydrochloride, which melts at 209 to 211 °C (408 to 412 °F) and is soluble in water and methanol and slightly soluble in ethanol.
=== April === 7 April – It was announced that the Leaving Certificate grinds school, the Institute of Education in Dublin with 7,000 pupils, founded by Ray Kearns in 1969, had been sold to a British educational company. 9 April – An emergency was declared and flights into Dublin Airport were suspended briefly when the nose landing gear of a Ryanair flight from Liverpool to Dublin experienced a problem during landing. Four other arriving flights were diverted to Shannon Airport. Visit by Joe Biden
== Applications == Despite the reduced efficiency verses reversed phase HPLC, hundreds of applications have been reported using MLC. One of the most advantageous is the ability to directly inject physiological fluids. Micelles have an ability to solubilize proteins which enables MLC to be useful in analyzing untreated biological fluids such as plasma, serum, and urine. Martinez et al. found MLC to be highly useful in analyzing a class of drugs called b-antagonists, so called beta-blockers, in urine samples. The main advantage of the use of MLC with this type of sample, is the great time savings in sample preparation. Alternative methods of analysis including reversed phase HPLC require lengthy extraction and sample work up procedures before analysis can begin. With MLC, direct injection is often possible, with retention times of less than 15 minutes for the separation of up to nine b-antagonists. Another application compared reversed phase HPLC with MLC for the analysis of desferrioxamine in serum. Desferrioxamine (DFO) is a commonly used drug for removal of excess iron in patients with chronic and acute levels. The analysis of DFO along with its chelated complexes, Fe(III) DFO and Al(III) DFO has proven to be difficult at best in previous attempts. This study found that direct injection of the serum was possible for MLC, verses an ultrafiltration step necessary in HPLC. This analysis proved to have difficulties with the separation of the chelated DFO compounds and with the sensitivity levels for DFO itself when MLC was applied.
The second phase uses a modified MaxSub algorithm: a single 7 reside aligned pair in each proteins is used to orient the two full length protein structures to maximally superimpose these just these 7 C-alpha, then in this orientation it scans for any additional aligned pairs that are close in 3D. It re-orients the structures to superimpose this expanded set and iterates until no more pairs coincide in 3D. This process is restarted for every 7 residue window in the seed alignment. The output is the maximal number of atoms found from any of these initial seeds. This statistic is converted to a calibrated E-value for the similarity of the proteins. Mammoth makes no attempt to re-iterate the initial alignment or extend the high quality sub-subset. Therefore, the seed alignment it displays can't be fairly compared to DALI or TM align as it was formed simply as a heuristic to prune the search space. (It can be used if one wants an alignment based solely on local structure-motif similarity agnostic of long range rigid body atomic alignment.) Because of that same parsimony, it is well over ten times faster than DALI, CE and TM-align. It is often used in conjunction with these slower tools to pre-screen large data bases to extract the just the best E-value related structures for more exhaustive superposition or expensive calculations.
=== Neurotransmission === Agmatine has been discussed as a putative neurotransmitter. It is synthesized in the brain, stored in synaptic vesicles, accumulated by uptake, released by membrane depolarization, and inactivated by agmatinase. Agmatine binds to α2-adrenergic receptor and imidazoline receptor binding sites, and blocks NMDA receptors and other cation ligand-gated channels. However, while agmatine binds to α2-adrenergic receptors, it exerts neither an agonistic nor antagonistic effect on these receptors, lacking any intrinsic activity. Apart from an absence of known agmatine-specific post-synaptic receptors, agmatine fulfills Henry Dale's criteria for a neurotransmitter and is hence considered a neuromodulator and co-transmitter. The existence of theoretical agmatinergic-mediated neuronal systems has not yet been demonstrated although the existence of such receptors is implied by its prominence in the mediation of both the central and peripheral nervous systems. Research into agmatine-specific receptors and transmission pathways continues. Due to its ability to pass through open cationic channels, agmatine has also been used as a surrogate metric of integrated ionic flux into neural tissue upon stimulation. When neural tissue is incubated in agmatine and an external stimulus is applied, only cells with open channels will be filled with agmatine, allowing identification of which cells are sensitive to that stimuli and the degree to which they opened their cationic channels during the stimulation period.
Sources: en.wikipedia.org
== History == Avasimibe was the result of a rational drug design process carried out at Parke-Davis in the early 1990s which sought to obtain orally bioavailable, water-soluble ACAT inhibitors; all such inhibitors known at the time were lipophilic and poorly absorbed when taken by mouth. This process yielded several compounds with potential, including one (designated PD 138142–15) with good solubility in water and remarkable efficacy in animal studies, but it was chemically unstable and degraded rapidly, especially in acidic environments. (Undesirable CYP450 induction was first noted at this time, in PD 138142-15 and its degradation products.) Chemical modification of PD 138142-15 and retrosynthetic analysis found that avasimibe (then codenamed CI-1011) could be easily manufactured from commercially available starting compounds, and once its efficacy was demonstrated in vitro and in rat studies, it was selected for further development. After additional safety and preclinical efficacy studies in animals, phase I clinical trials in humans began in 1997, first for hyperlipidemia (June) and subsequently for atherosclerosis (December). Phase II trials for both indications followed in 1998, and phase III trials in 2001. In October 2003, clinical development of avasimibe was discontinued. Later research discredited the concept of ACAT inhibition as a treatment for dyslipidemia and atherosclerosis, and interest in these compounds as a class waned accordingly.
Apples grown for consumption are suitable for cider making, though some regional cider-makers prefer to use a mix of eating and cider apples (as in Kent, England), or exclusively cider apples (as in the West Country, England and West of England). There are many hundreds of varieties of cultivars developed specifically for cider making.
The team under Wenger's management enjoyed another relatively strong league campaign in 2004–05, but finished second to Chelsea, who ended the season 12 points in front. Consolation again came in the FA Cup; Arsenal defeated Manchester United on penalties, after a goalless final. The emergence of Cesc Fàbregas in the starting line-up prompted Wenger to sell Vieira to Juventus in July 2005. He noticed the two as a midfield pairing was ineffective, and felt keeping Fàbregas would benefit the club's future. The 2005–06 season marked the beginning of a transitional period for Arsenal as it was the club's final season at Highbury. The team finished fourth in the Premier League and outside the top two for the first time under Wenger's tenure. In the Champions League, Wenger assembled an inexperienced defence that reached the final, beating Real Madrid, Juventus and Villarreal and conceding no goals in the knockout stages. In the final against Barcelona in May 2006, Arsenal took an early lead but ultimately lost the match 2–1. The defeat also made Wenger the only manager to have been a losing finalist in each of UEFA's three main club competitions, having previously lost the UEFA Cup final with Arsenal in 2000 and the Cup Winners' Cup final with Monaco in 1992.
The new 20th district encompasses downtown San Antonio and extends eastward to its historically Black east side and the community of Kirby, as well as westward to Leon Valley and several neighborhoods north of Lackland AFB. The incumbent is Democrat Joaquin Castro, who was re-elected unopposed in 2024. Kamala Harris won the two-thirds Hispanic district with 63.5% of the vote and Colin Allred 66.6% in 2024.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.